
1. clin liver dis. 2019 aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. epub 2019
may 24.

hbv/hdv coinfection: challenge therapeutics.

koh c(1), da bl(2), glenn js(3).

author information: 
(1)liver diseases branch, national institute diabetes digestive kidney
diseases, national institutes health, 10 center drive, building 10, room
9b-16, msc 1800, bethesda, md 20892, usa. electronic address:
christopher.koh@nih.gov.
(2)digestive diseases branch, national institute diabetes digestive and
kidney diseases, national institutes health, 10 center drive, crc, room
4-5722, bethesda, md 20892, usa.
(3)department medicine, division gastroenterology hepatology, stanford 
university school medicine, ccsr building, room 3115a, 269 campus drive,
stanford, ca 94305, usa; department medicine microbiology & immunology,
division gastroenterology hepatology, stanford university school of
medicine, ccsr building, rm. 3115a, 269 campus drive, stanford, ca 94305, usa.

chronic hepatitis (chd) results infection hepatitis b virus
and hepatitis virus (hdv). chd severe form human viral
hepatitis. current treatment options consist interferon alfa, is
effective minority patients. study hdv molecular virology has
resulted new approaches entering clinical trials, phase-3 studies the
most advanced. include entry inhibitor bulevirtide, nucleic acid
polymer rep 2139-ca, farnesyltransferase inhibitor lonafarnib, pegylated 
interferon lambda. article summarizes available data emerging
therapeutics.

published elsevier inc.

doi: 10.1016/j.cld.2019.04.005 
pmcid: pmc6659751
pmid: 31266627  [indexed medline]

